.svg)
Quick answer: The arachidonic acid pathway is a biochemical cascade that converts arachidonic acid, an omega-6 fatty acid stored in cell membranes, into inflammatory signaling molecules including prostaglandins, leukotrienes, and thromboxanes. It is a central mechanism of the acute inflammatory response and is relevant to conditions ranging from joint pain to cardiovascular risk. The balance between omega-6 and omega-3 fatty acids significantly influences how active this pathway is.
Why the Arachidonic Acid Pathway Matters
Inflammation is not a single process. It is a family of cascading molecular events, each serving distinct biological purposes. The arachidonic acid (AA) pathway is one of the most clinically important of these cascades: it produces the molecules that drive pain, swelling, fever, and platelet aggregation in response to injury or immune activation. It is also the pathway targeted by nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and aspirin, which work by blocking key enzymes in the cascade.
Understanding this pathway matters because chronic, low-grade activation of the AA cascade, as opposed to the acute, self-resolving inflammation it was designed to produce, is increasingly associated with cardiovascular disease, metabolic dysfunction, and chronic pain conditions. The dietary and metabolic inputs that drive or suppress this pathway are measurable and modifiable.
How the Arachidonic Acid Pathway Works
Where arachidonic acid comes from
Arachidonic acid is a 20-carbon omega-6 polyunsaturated fatty acid. It is stored in the phospholipid bilayer of nearly every cell membrane in the body. It enters the body through dietary sources of animal fat and linoleic acid (the parent omega-6 fatty acid found in vegetable oils), which is enzymatically converted to AA through a series of elongation and desaturation steps.
When a cell receives an injury or immune signal, an enzyme called phospholipase A2 (PLA2) cleaves arachidonic acid from the membrane, releasing it into the cytoplasm. This is the trigger that initiates the downstream cascade. Without this release step, the inflammatory molecules downstream cannot be produced.
The COX pathway: prostaglandins and thromboxanes
Once released, arachidonic acid is metabolized by one of two major enzyme families. Cyclooxygenase enzymes (COX-1 and COX-2) convert AA into prostaglandins and thromboxanes. These molecules mediate pain sensitization, fever, vasodilation at sites of inflammation, and platelet aggregation. COX-1 operates constitutively and plays a protective role in the gastric mucosa and platelet function. COX-2 is induced by inflammatory stimuli and is more specifically associated with the inflammatory response.
NSAIDs inhibit both COX enzymes to varying degrees. Aspirin irreversibly inhibits COX-1 and COX-2, which is why low-dose aspirin reduces platelet aggregation. Selective COX-2 inhibitors (such as celecoxib) were developed to reduce inflammatory symptoms while sparing the gastric-protective effects of COX-1.
The LOX pathway: leukotrienes
The second major branch uses lipoxygenase (LOX) enzymes to convert arachidonic acid into leukotrienes. These molecules play a prominent role in allergic inflammation, asthma, and the sustained phase of the inflammatory response. Leukotrienes increase vascular permeability, recruit neutrophils and eosinophils to sites of inflammation, and contribute to bronchoconstriction in asthma. Leukotriene-modifying drugs (such as montelukast) act specifically on this branch of the pathway.
The omega-3 counterbalance
Omega-3 fatty acids, particularly EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), compete with arachidonic acid at multiple steps in this pathway. EPA competes with AA for access to COX and LOX enzymes, producing a family of less inflammatory eicosanoids. When omega-3 intake is sufficient, a higher proportion of the resulting signaling molecules are derived from EPA rather than AA, resulting in a less pro-inflammatory eicosanoid profile.
A 2024 systematic review in Nutrients confirmed that omega-3 supplementation may reduce post-exercise inflammation and mitigate markers of muscle damage, effects mediated in part through competitive inhibition of the arachidonic acid pathway. The ratio of omega-6 to omega-3 fatty acids in the diet is therefore a meaningful determinant of background inflammatory tone.
Chronic activation and its consequences
The arachidonic acid pathway is designed for acute, resolving inflammation. Chronic stimulation, driven by high omega-6 intake, excess adipose tissue (which itself produces inflammatory cytokines), persistent infection, or metabolic dysfunction, maintains the pathway in a chronically active state. The resulting low-grade inflammatory environment is associated with cardiovascular risk, insulin resistance, and progression of conditions including atherosclerosis and inflammatory joint disease.
A 2024 study in the New England Journal of Medicine confirmed that combined assessment of inflammation (hs-CRP), LDL cholesterol, and lipoprotein(a) predicted 30-year cardiovascular outcomes in women, underscoring the relevance of chronic inflammatory pathway activity to long-term cardiovascular risk.
Which Biomarkers Reflect Arachidonic Acid Pathway Activity?
No single test directly measures arachidonic acid pathway activity in routine clinical practice, but several markers reflect the downstream consequences of chronic inflammatory cascade activation and the dietary inputs that modulate it.
- hs-CRP — Hepatic inflammation marker; rises in response to cytokines produced downstream of the AA pathway
- Omega-6 to omega-3 ratio — Direct measure of the fatty acid balance that determines the inflammatory tone of eicosanoid production; available via a fatty acid panel through provider referral
- Homocysteine — Elevated levels are associated with vascular inflammation and endothelial dysfunction
- Apolipoprotein B — Particle count measure; more sensitive than LDL for cardiovascular risk in inflammatory states
- Fasting insulin — Insulin resistance is a driver of chronic AA pathway activation via inflammatory adipokines
- HbA1c — Chronic hyperglycemia activates inflammatory pathways including COX-2 upregulation
Superpower's Baseline Blood Panel includes hs-CRP, homocysteine, fasting insulin, HbA1c, and ApoB, providing a baseline picture of chronic inflammatory tone and the metabolic conditions that drive the arachidonic acid pathway.
What Influences Arachidonic Acid Pathway Activity?
The primary modifiable inputs to the AA pathway are dietary fat composition (specifically the omega-6 to omega-3 ratio), body adiposity, blood sugar regulation, and the presence or absence of chronic infection or autoimmune activation. Reducing linoleic acid-heavy vegetable oil consumption relative to omega-3-rich sources, managing metabolic health, and addressing sources of chronic low-grade inflammation are the primary behavioral levers that affect this pathway.
None of this replaces a clinical assessment. Elevated hs-CRP, insulin resistance, or dyslipidemia require investigation of their specific sources before any conclusions about the AA pathway's role in any individual's health can be drawn.
This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to your health routine. Superpower offers blood panels that include the biomarkers discussed in this article. Links to individual tests are provided for informational context.
FAQs
The arachidonic acid pathway is a biochemical cascade in which the omega-6 fatty acid arachidonic acid is converted into eicosanoids, which are signaling molecules that regulate inflammation, blood clotting, and immune function. It matters for health because an imbalance in this pathway is associated with chronic low-grade inflammation, which has been linked to cardiovascular issues, metabolic conditions, and other long-term health concerns.
Arachidonic acid (AA) is a 20-carbon polyunsaturated omega-6 fatty acid found in cell membranes throughout the body. It is obtained directly from animal-based foods such as eggs, poultry, and red meat, and can also be synthesized in the body from linoleic acid, another omega-6 fat commonly found in vegetable oils. While it is essential for normal cellular function, its balance relative to omega-3 fatty acids like EPA is considered important for maintaining healthy inflammatory responses.
The three main enzymatic branches are the cyclooxygenase (COX) pathway, the lipoxygenase (LOX) pathway, and the cytochrome P450 pathway. The COX pathway produces prostaglandins and thromboxanes involved in inflammation and blood clotting, the LOX pathway generates leukotrienes that contribute to immune and allergic responses, and the cytochrome P450 pathway produces epoxyeicosatrienoic acids (EETs) that may help support vascular function.
Arachidonic acid serves as the primary substrate for producing pro-inflammatory eicosanoids such as prostaglandin E2 and leukotriene B4. When arachidonic acid levels are elevated relative to anti-inflammatory omega-3 fatty acids, the body may produce more of these pro-inflammatory mediators. This shift is associated with a heightened inflammatory state that, over time, may contribute to tissue damage and chronic health conditions.
An arachidonic acid blood test typically measures the concentration of arachidonic acid in red blood cell membranes or plasma, often reported alongside other fatty acids. Many panels also calculate the AA/EPA ratio, which compares your arachidonic acid level to your eicosapentaenoic acid (EPA) level. This ratio is used as a marker of omega-6 to omega-3 balance and may reflect your overall inflammatory status.
The AA/EPA ratio compares the amount of arachidonic acid (an omega-6 fat) to eicosapentaenoic acid (an omega-3 fat) in your blood. A higher ratio suggests a greater proportion of pro-inflammatory omega-6 relative to anti-inflammatory omega-3, which is associated with increased inflammatory activity. Tracking this ratio over time may help you evaluate whether dietary changes, such as increasing fish intake or omega-3 supplementation, are shifting your fatty acid balance in a favorable direction.
References
- Ricciotti, E., & FitzGerald, G. A. (2011). Prostaglandins and inflammation. Arteriosclerosis, thrombosis, and vascular biology, 31(5), 986-1000. https://doi.org/10.1161/ATVBAHA.110.207449
- Wang, B., Wu, L., Chen, J., Dong, L., Chen, C., Wen, Z., Hu, J., Fleming, I., & Wang, D. W. (2021). Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets. Signal transduction and targeted therapy, 6(1), 94. https://doi.org/10.1038/s41392-020-00443-w
- Murakami, M., & Kudo, I. (2002). Phospholipase A2. Journal of biochemistry, 131(3), 285-92. https://doi.org/10.1093/oxfordjournals.jbchem.a003101
- Calder, P. C. (2017). Omega-3 fatty acids and inflammatory processes: from molecules to man. Biochemical Society transactions, 45(5), 1105-1115. https://doi.org/10.1042/BST20160474
- Fernández-Lázaro, D., Arribalzaga, S., Gutiérrez-Abejón, E., Azarbayjani, M. A., Mielgo-Ayuso, J., & Roche, E. (2024). Omega-3 Fatty Acid Supplementation on Post-Exercise Inflammation, Muscle Damage, Oxidative Response, and Sports Performance in Physically Healthy Adults-A Systematic Review of Randomized Controlled Trials. Nutrients, 16(13). https://doi.org/10.3390/nu16132044
- Ridker, P. M., Moorthy, M. V., Cook, N. R., Rifai, N., Lee, I. M., & Buring, J. E. (2024). Inflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women. The New England journal of medicine, 391(22), 2087-2097. https://doi.org/10.1056/nejmoa2405182
.avif)
.svg)
.svg)
